Initiation of SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and chronic kidney disease in China is associated with improved clinical outcomes.
What are the clinical characteristics, outcomes, and healthcare resource utilization of patients with T2D and CKD initiating SGLT2i or GLP-1 RA?
This study provides descriptive real-world evidence on the characteristics, healthcare resource utilization, and residual risks of Chinese patients with T2D and CKD initiating SGLT2i or GLP-1 RA.
Absolute Event Rate: 0% vs 0%
This study provides descriptive evidence regarding the clinical characteristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understanding the existing HRU and residual risk of severe clinical outcomes in such patient populations. The findings also provide a solid foundation for future research aimed at examining the clinical outcomes of new therapeutic options for T2D and CKD.
Deng et al. (Wed,) reported a other. Initiation of SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and chronic kidney disease in China is associated with improved clinical outcomes.